Zephyrus Biosciences Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 12
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $15M
Latest Deal Amount

Zephyrus Biosciences General Information

Description

Provider of medical research tools created to help in the research of single-cell analysis. The company's research tools enable western blotting on individual cells enabling researchers to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 1250 Shattuck Avenue
  • PH Suite
  • Berkeley, CA 94709
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zephyrus Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 14-Mar-2016 $15M 00.00 0000 Completed Startup
3. Grant 10-Sep-2014 00000 00.00 Completed Startup
2. Seed Round 10-Sep-2014 $1.5M $1.5M 00.000 Completed Startup
1. Angel (individual) Completed Startup
To view Zephyrus Biosciences’s complete valuation and funding history, request access »

Zephyrus Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00.00 00.00 00.000
To view Zephyrus Biosciences’s complete cap table history, request access »

Zephyrus Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of medical research tools created to help in the research of single-cell analysis. The company's research tools
Biotechnology
Berkeley, CA
12 As of 2016
00.00
000 0000-00-00
000000&0 00.00

000 0000

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000000000000
Pleasanton, CA
000 As of 0000
00.000
00000000 00.000

0000000

i ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000000 - 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zephyrus Biosciences Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
10x Genomics Formerly VC-backed Pleasanton, CA 000 00.000 00000000 00.000
0000000 Venture Capital-Backed Cambridge, MA 00 00000 000000000 - 00000
00000000 000000 Formerly VC-backed Emeryville, CA 000 00000 00000000 00000
00000000 00 Corporate Backed or Acquired Cambridge, United Kingdom 00 00000 00000000
00000 00000000000 Venture Capital-Backed San Francisco, CA 00 0000 00000000000 0000
You’re viewing 5 of 8 competitors. Get the full list »

Zephyrus Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zephyrus Biosciences Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BayBio FAST Accelerator/Incubator Minority 000 0000 000000 0
Berkeley SkyDeck Accelerator/Incubator Minority 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator Minority 000 0000 000000 0
Codon Capital Venture Capital Minority 000 0000 000000 0
David Beyer Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »